Aura Biosciences to repurchase ~6.9M shares from Matrix Capital at $5.64; reports preliminary cash of $114.7M

Aura Biosciences, Inc.

Enters stock purchase agreement to repurchase up to 6,922,870 shares from Matrix Capital Master Fund at $5.64 per share, matching equity offering price.
Repurchase conditioned on closing of equity offering; expected after offering closing. Matrix held 10.8% of outstanding shares pre-transaction.
Preliminary cash, cash equivalents, and marketable securities as of March 31, 2026: approximately $114.7 million (unaudited).
Repurchase funded by net proceeds from equity offering exceeding $200M; shares become authorized but unissued.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aura Biosciences, Inc. entered into Repurchase Agreement with Matrix Capital Management Master Fund, LP (effective 2026-04-30).

Action: entry
Agreement: equity purchase
Counterparty: Matrix Capital Management Master Fund, LP
Effective: 2026-04-30

Exact text from the filing

On April 30, 2026, Aura Biosciences, Inc. (the “Company”) and Matrix Capital Management Master Fund, LP (“Matrix”) entered into a stock purchase agreement (the “Repurchase Agreement”)

View on SEC.gov

Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.